PDGFRB and adrenal cortex carcinoma: Axitinib (AG-013736) is an oral, potent, and selective oral inhibitor of VEGFR tyrosine kinases 1, 2, 3.[62] In phase II study, axitinib administered to 13 patients with metastatic or locally advanced ACC resulted in no responses.[63] Sorafenib, an inhibitor of several tyrosine kinase receptors such as VEGFR2, VEGFR3, platelet-derived growth factor receptor (PDGFR), and RAF-1, was investigated in a phase II trial in combination with paclitaxel for patients with advanced disease and showed no clinical activity.